Soham D. Puvvada

AstraZeneca (Netherlands) — Netherlands

Medicine · Health Sciences

22h-index5.4kcitations105works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(43), Chronic Lymphocytic Leukemia Research(31), Lung Cancer Treatments and Mutations(24), HER2/EGFR in Cancer Research(23), Monoclonal and Polyclonal Antibodies Research(12)

Publications105 total

145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1
Annals of Oncology·2025· 1 cited
957P Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis
Annals of Oncology·2025
Abstract CT249: An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Cancer Research·2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Advances in Therapy·2025· 3 citedOpen Access
An Open-Label, Multicentre, Phase 2 Study Of Trastuzumab Deruxtecan In Patients With HER2-Expressing Solid Tumours: DESTINY-PanTumor02 Part 2
International Journal of Gynecological Cancer·2025Open Access
400TiP An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Annals of Oncology·2024· 1 citedOpen Access
Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
Gynecologic Oncology·2024· 3 cited
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Advances in Therapy·2024· 21 citedOpen Access
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Journal of Clinical Oncology·2024· 10 cited
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).
Journal of Clinical Oncology·2024· 2 cited
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Journal of Clinical Oncology·2024· 5 cited
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
2024Open Access
74MO Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Annals of Oncology·2023Open Access
PO007LBA/#1550  Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study
2023Open Access
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology·2023· 771 citedOpen Access
LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Annals of Oncology·2023· 3 citedOpen Access
148P DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Annals of Oncology·2023· 1 citedOpen Access
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Journal of Clinical Oncology·2023· 82 cited
Figure S2 from Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
2023Open Access
Figure S1 from Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Daniel O. Persky(12), Funda Meric‐Bernstam(11), Jonathan W. Friedberg(9), Jonathan H. Schatz(9), Andrew W. Roberts(8), Brad S. Kahl(8), William G. Wierda(8), John F. Seymour(8), Iwona Ługowska(8), Daniil Stroyakovskiy(8), Lisa M. Rimsza(8), Ming Zhu(7), Vicky Makker(7), Ana Oaknin(7), Kyung Hae Jung(7), Salvatore Siena(7), Matthew S. Davids(6), John F. Gerecitano(6), Lori A. Gressick(6), Martin Dunbar(6)